Exchange: NASDAQ·Updated 07:30 PM EDT

BNOX Bionomics ADS

$3.79
$0.03
(0.80%)
Today
Closed $3.79
$0.00
(0.00%)
After Hours
Mkt Cap$20.32M
Vol20,827.00

About BNOX

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
43

Bearish Sentiment

How do you feel about BNOX?

Advertisement|Remove ads.